Edgar Filing: ANTARES PHARMA, INC. - Form 4

ANTARES P	HARMA, INC.									
Form 4										
May 16, 2008	3									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								COMMISSION	OMB APPROVAL	
						n, D.C. 20549			OMB Number:	3235-0287
Check this if no long subject to Section 16 Form 4 or	er STATEM	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires:January 31, 2005Estimated average burden hours per response0.5	
Form 5 obligation may conti <i>See</i> Instru- 1(b).	s Section 17(a	Public Ut		pany	Act of	e Act of 1934, f 1935 or Sectio 40	n			
(Print or Type R	esponses)									
STOVER JACK E Sym			Symbol	2. Issuer Name and Ticker or Trading Symbol ANTARES PHARMA, INC. [AIS]				5. Relationship of Reporting Person(s) to Issuer		
(Last)	(First) (M	iddle)		Earliest Tra		L	-	(Chec	k all applicable	e)
				th/Day/Year)				X Director 10% Owner X Officer (give title Other (specify below) Delow) President and CEO		
	(Street)	(Street) 4. If Amend Filed(Month			-			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
EWING, NJ	08618								fore than One Re	
(City)	(State) (2	Zip)	Table	e I - Non-D	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	n Date, if	3. Transactic Code (Instr. 8) Code V	on(A) or Dis (D) (Instr. 3, 4 Amount	sposed	l of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	
Common Stock	05/14/2008			А	60,000 (1)	А	<u>(2)</u>	276,666	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative Expiration Date **Underlying Securities** (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Securities (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Acquired (A) or Derivative Disposed of (D) Security (Instr. 3, 4, and 5) Amount or Date Expiration Title Number of Exercisable Date (D) Code V Shares (A) Stock Option Common (3) 05/13/2018 \$ 0.85 05/14/2008 180,000 180,000 Α (right to Stock buy)

Edgar Filing: ANTARES PHARMA, INC. - Form 4

Reporting O	wners
-------------	-------

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
STOVER JACK E C/O ANTARES PHARMA, INC. 250 PHILLIPS BLVD, SUITE 290 EWING, NJ 08618	Х		President and CEO				
Signatures							
Robert F. Apple as attorney-in-fact f Stover		05/16/2008					
<u>*</u>Signature of Reporting Person			Date				

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents grant of shares of restricted Common Stock issued under the 2008 Equity Compensation Plan. The shares vest in three equal annual installments.
- (2) Not applicable.
- (3) The option vests in equal quarterly installments over three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.